Vaxart, Inc. (VXRT) Q4 2025 Earnings Call Transcript

Vaxart, Inc.'s Q4 2025 earnings call highlighted significant advancements in their oral vaccine development and a promising pipeline that attracted investor interest. The company reported a narrower-than-expected loss and reaffirmed guidance for upcoming clinical trials that may bolster revenue. Despite the positive results, concerns linger regarding competition in the vaccine industry and regulatory hurdles. The management remains optimistic about potential partnerships to enhance product distribution. Overall, the sentiment leans cautiously optimistic, with analysts monitoring the competitive landscape closely.